Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Cardiff University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Cardiff University
ClinicalTrials.gov Identifier:
NCT00851942
First received: February 25, 2009
Last updated: February 24, 2010
Last verified: February 2009
  Purpose

Synacthen® is a synthetic analogue of ACTH which has been used since the 1960s to assess adrenal sufficiency. It is now well established as a first line test to investigate diseases of the hypothalamo-pituitary-adrenal axis and to assess adrenal function in patients on long-term corticosteroid therapy. Briefly, cortisol is measured before and after injection of 250 micrograms of Synacthen®. In a normal individual serum cortisol will rise to concentrations greater than an arbitrary value (typically 550 nmol/l) 30 minutes after administration of Synacthen®.

In 2004 the All Wales Clinical Biochemistry Audit group surveyed protocols for performing and interpreting short Synacthen® tests. This identified wide differences in practice within Wales. As a result standards were drawn up for performance of the test. It was noted that there was considerable variability or bias between cortisol immunoassays and that the cortisol cut-off chosen for interpretation of the short Synacthen® test should be method dependent.

Clark et al., in 1998 reported cortisol cut-offs following Synacthen® using 4 well established commercially available cortisol immunoassays. This study demonstrated considerable differences between the cortisol immunoassays used in clinical laboratories at the time. It was also apparent that there were differences in gender-related responses to Synacthen® although there was no dependence on age. In the 8 years since publication of this study there have been advances in formulation of cortisol immunoassays as well as the instrumentation used to perform analyses. At the University Hospital of Wales cortisol is currently assayed using the Bayer Centaur automated immunoassay analyser. This assay was not available at the time of the study by Clark et al.,. The investigators' current short Synacthen® test cut-offs therefore rely on historical reference ranges which have become outdated. A re-evaluation of the cortisol cut-off is required to ensure that patients are not incorrectly classified.

It has been long been recognised that oestrogens (including ethinyloestradiol prescribed in combined oral contraceptive pills) increase total (but not free) serum cortisol levels. The degree of increase is related to the dose used and is thought to be due to an elevation in cortisol binding globulin (CBG). However, no comparisons of total serum cortisol in response to Synacthen® have been performed between women taking oestrogens and those who are not. Knowledge of the salivary cortisol response may also be useful in patients with decreased serum CBG concentrations e.g. severe nephrotic syndrome in whom the serum cortisol response may be misleading. The investigators therefore plan to measure salivary cortisol as part of the investigators' study protocol to assess the response of free cortisol.

17 Hydroxyprogesterone (17OHP) is an intermediate in the biosynthesis of cortisol. Deficiency of 21-hydroxylase enzyme activity leads to an increased concentration of 17OHP in the peripheral circulation. The short Synacthen® test can be used to assist in diagnosis of mild cases of congenital adrenal hyperplasia. Current reference ranges are taken from the literature.


Condition Intervention Phase
Healthy
Adrenal Insufficiency
Hypopituitarism
Drug: Synacthen (Tetracosactrin)
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test

Resource links provided by NLM:


Further study details as provided by Cardiff University:

Primary Outcome Measures:
  • The primary end-point of the study will be to establish method dependent cortisol cut offs for the normal response to Synacthen® using the 5th percentile. [ Time Frame: Cortisol response at 30 minutes ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Cortisol measurements by immunoassay will be compared with the GC-MS gold standard method for normal volunteers and patients with hypopituitarism and hypoadrenalism. [ Time Frame: Cortisol response at 30 minutes ] [ Designated as safety issue: No ]
  • Synacthen® responses in women taking ethinyloestradiol-containing contraceptive pills will be compared with those who are not. [ Time Frame: Cortisol response at 30 minutes ] [ Designated as safety issue: No ]
  • We will establish cut offs for the salivary cortisol response to Synacthen® in normal volunteers using the 5th percentile. [ Time Frame: Cortisol response at 30 minutes ] [ Designated as safety issue: No ]
  • We will establish a 17OHP cut off in response to Synacthen® in normal female volunteers using the 5th percentile. [ Time Frame: 17OHP response at 60 minutes ] [ Designated as safety issue: No ]

Estimated Enrollment: 240
Study Start Date: September 2008
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Synacthen (Tetracosactrin)
    IV injection of 250 micrograms of Synacthen in 1ml
    Other Name: Synacthen
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Volunteers will be in self-proclaimed good health
  • Volunteers will be free of illness on the day of testing
  • Volunteers will not be taking drug therapy.
  • Patients will be free of intercurrent illness on the day of testing
  • Patients will have a confirmed diagnosis of hypoadrenalism or hypopituitarism

Exclusion Criteria:

  • Is pregnant or lactating. Females of childbearing potential must have a negative pregnancy test before enrollment onto the study. Non-child bearing potential is defined as post-menopausal for at least 1 year, surgical sterilisation or hysterectomy at least three months before the start of the study,
  • Is using corticosteroids,
  • has any significant intercurrent disease,
  • has a history of thyroid or other autoimmune disease,
  • has a previous history of hypersensitivity to Synacthen®,
  • has a previous history of asthma
  • has a history of allergic disorder
  • has any mental condition rendering the patient unable to understand the nature or possible consequences of the study, and/or evidence of an uncooperative attitude.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00851942

Locations
United Kingdom
Clinical Research Facility, University Hospital of Wales
Cardiff, South Glamorgan, United Kingdom, CF14 4XW
Sponsors and Collaborators
Cardiff University
Investigators
Principal Investigator: Aled Rees, MB BCh, PhD Cardiff University
  More Information

No publications provided by Cardiff University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr Aled Rees, Cardiff University
ClinicalTrials.gov Identifier: NCT00851942     History of Changes
Other Study ID Numbers: SPON 431-07
Study First Received: February 25, 2009
Last Updated: February 24, 2010
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Cardiff University:
Volunteer
Hypoadrenalism
Hypopituitarism
Healthy volunteers

Additional relevant MeSH terms:
Adrenal Insufficiency
Addison Disease
Hypopituitarism
Adrenal Gland Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Cosyntropin
Hydrocortisone
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 15, 2014